nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Accelerating Availability of new Vaccines: The Role of the International Community*
|
Milstien, Julie B. |
|
1998 |
32 |
1 |
p. 175-182 |
artikel |
2 |
Adverse Drug Reactions: The Great Masqueraders
|
Routledge, P. A. |
|
1998 |
32 |
1 |
p. 79-84 |
artikel |
3 |
An Analysis of Class I Recalls: 1982–1996*
|
Rumore, Martha M. |
|
1998 |
32 |
1 |
p. 65-71 |
artikel |
4 |
An Historical Perspective of the Successful Development of Sevoflurane
|
Callan, Clair |
|
1998 |
32 |
1 |
p. 119-127 |
artikel |
5 |
Assessment of Generic Drugs in the Caribbean
|
Pereira, Lexley M. Pinto |
|
1998 |
32 |
1 |
p. 145-150 |
artikel |
6 |
A Statistical Evaluation of the Chemical Composition of Heroin Samples with the View to Discriminating between their Possible Sources
|
Ekangaki, A. |
|
1998 |
32 |
1 |
p. 229-241 |
artikel |
7 |
A Systems Infrastructure for Sponsor/CRO Collaboration on International Clinical Trials
|
Schoichet, Sandor |
|
1998 |
32 |
1 |
p. 155-161 |
artikel |
8 |
Cancer Drug Development: Problems and Opportunities
|
Markman, Maurie |
|
1998 |
32 |
1 |
p. 1-5 |
artikel |
9 |
CDER/FDA Formats for Submission of Animal Carcinogenicity Study Data*
|
Lin, Karl K. |
|
1998 |
32 |
1 |
p. 43-52 |
artikel |
10 |
Changing the Review Process: The View of the Japanese Ministry of Health and Welfare
|
Hirayama, Yoshinobu |
|
1998 |
32 |
1 |
p. 111-117 |
artikel |
11 |
Clinical Trials in Central/Eastern Europe: Industry Viewpoint
|
Natorff, Benona Lillian |
|
1998 |
32 |
1 |
p. 129-133 |
artikel |
12 |
Detection of an Outlier and Evaluation of its Influence in Chronic Toxicity Studies
|
Hamada, Chikuma |
|
1998 |
32 |
1 |
p. 201-212 |
artikel |
13 |
Development of ADR Monitoring Activities in Poland Subsequent to Changes in the Pharmaceutical Market
|
Czarnecki, Andrzej |
|
1998 |
32 |
1 |
p. 73-77 |
artikel |
14 |
Drug Information Clerkships in the Pharmaceutical Industry*
|
Fus, Andrea F. |
|
1998 |
32 |
1 |
p. 305-311 |
artikel |
15 |
Drug Metabolism in Drug Development: A DIA Tutorial for Regulatory Affairs Specialists*
|
Honig, Peter K. |
|
1998 |
32 |
1 |
p. 163-167 |
artikel |
16 |
ELI Lilly and Company Global Medical Information: Pharmacy Student Clerkships in Industry
|
Riggins, Jennifer L. |
|
1998 |
32 |
1 |
p. 283-288 |
artikel |
17 |
Expectations for an International Harmonized Guideline
|
Sato, Tosiya |
|
1998 |
32 |
1 |
p. 135-139 |
artikel |
18 |
Faster Access to Drugs for Serious or Life-Threatening Illnesses through use of the Accelerated Approval Regulation in the United States
|
Cocchetto, David M. |
|
1998 |
32 |
1 |
p. 27-35 |
artikel |
19 |
Further Statistical Issues in Project Prioritization in the Pharmaceutical Industry
|
Senn, Stephen |
|
1998 |
32 |
1 |
p. 253-259 |
artikel |
20 |
Impact of the ICH Guideline on Ethnic Differences
|
Dumitriu, Helene |
|
1998 |
32 |
1 |
p. 141-144 |
artikel |
21 |
Interpretation of Subgroup Analyses in Medical Device Clinical Trials*
|
Scott, Pamela E. |
|
1998 |
32 |
1 |
p. 213-220 |
artikel |
22 |
Labeling of Drug and Biologic Products for Pediatric Use
|
Shacter, Emily |
|
1998 |
32 |
1 |
p. 299-303 |
artikel |
23 |
Medical Information on Demand
|
Gaspic, Mary |
|
1998 |
32 |
1 |
p. 289-292 |
artikel |
24 |
Orphan Drug Development — International Program and Study Design Issues
|
Haffner, Marlene E. |
|
1998 |
32 |
1 |
p. 93-99 |
artikel |
25 |
Pharmacoeconomic Evaluation in Japanese Pharmaceutical Companies
|
Ikeda, Shunya |
|
1998 |
32 |
1 |
p. 169-174 |
artikel |
26 |
Preparing an Integrated Summary of Safety: A Writer's Perspective
|
Myers, Sharie |
|
1998 |
32 |
1 |
p. 53-63 |
artikel |
27 |
Project Management in Pharmaceutical Biometry and Data Management: Conception, Implementation, and Operations
|
Wilhelm, Martin |
|
1998 |
32 |
1 |
p. 221-228 |
artikel |
28 |
Proposed Statistical Methods for Signal Detection of Adverse Medical Device Events
|
Lao, Chang S. |
|
1998 |
32 |
1 |
p. 183-191 |
artikel |
29 |
Quality Criteria and Standardization of Phytopharmaceuticals: Can Acceptable Drug Standards be Achieved?
|
Bauer, Rudolf |
|
1998 |
32 |
1 |
p. 101-110 |
artikel |
30 |
Sample Size Estimation when Comparing More than two Treatment Groups
|
Phillips, Alan |
|
1998 |
32 |
1 |
p. 193-199 |
artikel |
31 |
Statistics and Statisticians in European Drug Regulatory Agencies
|
Köpcke, Wolfgang |
|
1998 |
32 |
1 |
p. 243-251 |
artikel |
32 |
Technologies for Automating Randomized Treatment Assignment in Clinical Trials
|
Haag, Uwe |
|
1998 |
32 |
1 |
p. 7-11 |
artikel |
33 |
The Challenge of the Internet
|
Pines, Wayne L. |
|
1998 |
32 |
1 |
p. 277-281 |
artikel |
34 |
The Drug Information Service at a University Hospital in Malaysia: Characteristics of Drug Inquiries
|
Rahman, Ab Fatah Ab |
|
1998 |
32 |
1 |
p. 293-298 |
artikel |
35 |
The Emerging Role of Herbal Medicine in Health Care in Europe
|
Gruenwald, Joerg |
|
1998 |
32 |
1 |
p. 151-153 |
artikel |
36 |
The Need for and Design of Combination Vaccines
|
Hausdorff, William P. |
|
1998 |
32 |
1 |
p. 13-17 |
artikel |
37 |
Transfer of Processes from Development to Manufacturing
|
Gerson, Donald F. |
|
1998 |
32 |
1 |
p. 19-26 |
artikel |
38 |
Understanding the Interfaces among Multiple Technical Disciplines: An Increasing Challenge for Regulatory Affairs
|
Cocchetto, David M. |
|
1998 |
32 |
1 |
p. 37-41 |
artikel |
39 |
Using Tolerance Limits to Evaluate Laboratory Data
|
Nickens, Dana J. |
|
1998 |
32 |
1 |
p. 261-269 |
artikel |
40 |
What does the Over-The-Counter Industry in Europe Need?
|
Cranz, Hubertus |
|
1998 |
32 |
1 |
p. 271-275 |
artikel |
41 |
Working Methods for the Adverse Drug Reaction Monitoring Program in the Philippines
|
Hartigan-Go, Kenneth |
|
1998 |
32 |
1 |
p. 85-92 |
artikel |